contains the active ingredient Ceftazidime pentahydrate
CONSUMER MEDICINE INFORMATION
NOTICE: This Consumer Medicine Information (CMI) is intended for persons
living in Australia. This page contains answers to some common
. It does
not contain all the information that is known about
. It does not take the
place of talking to your doctor or pharmacist. All medicines have risks
and benefits. Your doctor has weighed the risk of you using this medicine
against the benefits he/she expects it will have for you. If you have
any concerns about using this medicine, ask your doctor or pharmacist.
Bookmark or print this page, you may need to read it again.
What CEFTAZIDIME MYLAN is used for
CEFTAZIDIME MYLAN contains ceftazidime (as pentahydrate) as the active ingredient. It belongs to a group of antibiotics called
It is used to treat a wide range of infections caused by bacteria. These infections may affect the chest (bronchitis or pneumonia),
ears, nose, throat, bladder and urinary tract, skin and soft tissue, stomach or bones.
It works by killing the bacteria that cause these.
Ask your doctor if you have any questions about why this medicine has been prescribed for you.
Your doctor may have prescribed it for another reason.
This medicine/It is available only with a doctor's prescription.
This medicine is not addictive.
Before you are given it
When you must not be given it
You must not be given CEFTAZIDIME MYLAN if you have or have had an allergy to:
any medicine containing ceftazidime
any other cephalosporin antibiotic
major allergy to penicillin
If you are allergic to cephalosporin or penicillin you may have an increased chance of being allergic to CEFTAZIDIME MYLAN.
Any of the ingredients listed at the end of this leaflet.
Some of the symptoms of an allergic reaction may include;
shortness of breath
wheezing or difficulty breathing
swelling of the face, lips, tongue or other parts of the body
rash, itching or hives on the skin
CEFTAZIDIME MYLAN should not be mixed with lignocaine and given to you if you have had an allergic reaction to lignocaine.
Lignocaine is sometimes mixed with CEFTAZIDIME MYLAN to reduce pain when injected into muscle.
You must not be given this medicine after the expiry date printed on the pack of if the packaging is torn or shows signs of
The active ingredient in CEFTAZIDIME MYLAN passes into breast milk (if applicable) and there is a possibility that your baby
may be affected.
Do not take this medicine after the expiry date printed on the pack or if the packaging is torn or shows signs of tampering.
If it has expired or is damaged, return it to your pharmacist for disposal.
If you are not sure whether you should start taking this medicine, talk to your doctor.
Before you start to take it
Tell your doctor if you have allergies to any other medicines, foods, preservatives or dyes.
Tell your doctor if you have or have had any of the following medical conditions:
a reaction to any other antibiotic (particularly a penicillin), even if it was not a serious reaction
you have had to stop taking another medicine for this or any other infection
kidney or liver problems
stomach or bowel illness (e.g. colitis)
you test your urine for sugar
blood clotting disorder
while on CEFTAZIDIME MYLAN, you need to have your blood tested for a blood transfusion
you have been taking an antibiotic for a prolonged time
Tell your doctor if you are pregnant or plan to become pregnant or are breastfeeding.
Your doctor can discuss with you the risks and benefits involved.
It is not recommended for use while breastfeeding as it is found in breast milk.
If you have not told your doctor about any of the above, tell him/her before you start taking CEFTAZIDIME MYLAN.
Taking other medicines
Tell your doctor or pharmacist if you are taking any other medicines, including any that you get without a prescription from
a pharmacy, supermarket or health food shop.
Some medicines and CEFTAZIDIME MYLAN may interfere with each other. These include:
chloramphenicol, an antibiotic used to treat bacterial infections
diuretics, a medicine which helps to reduce the amount of excess fluid in the body by increasing the amount of urine produced
aminoglycosides, an antibiotic used to treat serious bacterial infections
any other antibiotic
These medicines may be affected by CEFTAZIDIME MYLAN or may affect how well it works. You may need different amounts of your
medicines, or you may need to take different medicines.
Your doctor and pharmacist have more information on medicines to be careful with or avoid while taking this medicine.
Talk to your doctor about the need for an additional method of contraception while being on CEFTAZIDIME MYLAN.
Some antibiotics may decrease the effectiveness of some birth control pills, although this has not been shown with CEFTAZIDIME
How to take CEFTAZIDIME MYLAN
How much to take
Your doctor will decide what dose you will receive. This depends on the condition being treated and your response to the treatment.
Your doctor may change the dose and frequency of your medicine as your condition changes. If you have kidney problems, your
doctor may lower the dose and frequency of administration.
How to take it
CEFTAZIDIME MYLAN will be injected into a muscle or into a vein. When it is injected into a vein it may be given directly
or through a 'drip'.
CEFTAZIDIME MYLAN will be prepared and given to you by a doctor or nurse. You will not be expected to give yourself this medicine.
If you take too much (overdose)
As CEFTAZIDIME MYLAN is given to you under the supervision of your doctor, it is extremely unlikely that you will be given
However, if you experience any side effects after being given this medicine, tell your doctor or nurse immediately.
Symptoms of an overdose may include fits and loss of consciousness.
Immediately telephone your doctor or the Poisons Information Centre (telephone 13 11 26) for advice, or go to Accident and
Emergency at the nearest hospital, if you think that you or anyone else may have taken too much CEFTAZIDIME MYLAN. Do this
even if there are no signs of discomfort or poisoning.
While you are taking CEFTAZIDIME MYLAN
Things you must do
Tell your doctor if the symptoms of your infection do not improve within a few days or if they become worse.
Tell your doctor or pharmacist if you have severe diarrhoea or any diarrhoea that persists for more than a day or so.
Do this even if it occurs several weeks after stopping treatment with CEFTAZIDIME MYLAN.
Do not take any medicines for diarrhoea without first checking with your doctor.
Diarrhoea may mean that you have a serious condition affecting your bowel. You may need urgent medical care.
Tell your doctor if you get a sore white mouth or tongue or a vaginal itching or discharge during or soon after stopping treatment
with CEFTAZIDIME MYLAN.
This may mean you have a fungal infection called thrush. This medicine will not kill fungi and you may need other treatment.
If you are about to have any blood tests, tell your doctor that you have been treated with CEFTAZIDIME MYLAN.
It may interfere with the results of some tests.
If you are diabetic, check with your doctor or pharmacist before using urine sugar tests.
CEFTAZIDIME MYLAN may cause false test results with some urine sugar tests.
Things to be careful of
Be careful driving or operating machinery until you know how CEFTAZIDIME MYLAN affects you.
CEFTAZIDIME MYLAN may cause dizziness in some people. If you experience symptoms such as this, do not drive, operate machinery
or do anything else that could be dangerous.
Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking CEFTAZIDIME MYLAN.
All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical attention
if you get some of the side effects.
Tell your doctor or pharmacist if you notice any of the following and they worry you:
pain or flaking skin where you had the injection
numbness or tingling
nausea (feeling of sickness) or vomiting
bad taste in mouth.
The above list includes the more common side effects of your medicine.
Tell your doctor as soon as possible if you notice any of the following:
sore mouth or tongue
vaginal discharge, genital itching.
The above list includes serious side effects that may require medical attention.
Tell your doctor immediately, or go to Accident and Emergency at your nearest hospital if you notice any of the following
allergic-type reactions such as difficulty breathing, wheezing, swelling of the eyelids, face or lips, fever, fainting, itching,
rash or hives, red spots, skin lumps, blisters or peeling.
diarrhoea, particularly if bloody or watery and if you also have stomach cramps or a high temperature (even several weeks
after your CEFTAZIDIME MYLAN treatment)
bruising or bleeding
shaking or muscle twitches.
These are rare but serious side effects. You may need urgent medical attention.
Tell your doctor if you notice anything else that is making you feel unwell, even if you think the problems are not connected
with this medicine and are not referred to in this leaflet.
Other side effects not listed above may also occur in some people.
Do not be alarmed by the following list of side effects.
You may not experience any of them.
After taking CEFTAZIDIME MYLAN
CEFTAZIDIME MYLAN will be stored in the pharmacy or on the ward. It should be protected from light and kept in a cool dry
place where the temperature stays below 25°C.
What it looks like
CEFTAZIDIME MYLAN is available in two strengths: 1 g or 2 g.
Both strengths are a white or almost white powder for injection in clear glass vials.
Available in packs of 1and 5 vial.
Before use, the doctor or nurse will mix CEFTAZIDIME MYLAN powder with a sterile fluid to form a solution for injection.
Each vial contains either 1 g or 2 g of ceftazidime (as pentahydrate).
Alphapharm Pty Limited
(ABN 93 002 359 739)
Level 1, 30 The Bond
30-34 Hickson Road
Millers Point NSW 2000
Phone: (02) 9298 3999
Australian registration numbers:
CEFTAZIDIME MYLAN ceftazidime (as pentahydrate) 1 g powder for injection vial: AUST R 154825
CEFTAZIDIME MYLAN ceftazidime (as pentahydrate) 2 g powder for injection vial: AUST R 154824
This leaflet was prepared on
12 August 2015.